Jilian Golding

Global Commercial Strategy, Precision Medicine Lead Bristol Myers Squibb

Wednesday 7th October 2026

Panel Discussion: Bolstering Scalable Commercial Drug-Diagnostic Strategies to Ensure Equitable Solutions for Global Precision Oncology Applications

3:10 pm

How can biopharma and diagnostics partners truly synchronize drug-CDx launches to avoid misalignment in assay availability, regulatory timing, and clinical adoption across markets?
What are the biggest barriers to global drug-CDx adoption at launch, and how can they be proactively addressed within commercialization strategies?
In an increasingly complex global landscape, how can organizations balance the need for standardized CDx strategies with local market realities to achieve equitable patient access?

Thursday 8th October 2026

Panel Discussion: Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers

9:00 am

What is the PCC, our mission, and why is a consortium driving the charge for comprehensive biomarker testing?